Concepedia

Sam Haidar

SH

31

Publications

1.6K

Citations

26

H-Index

1995

Active since

Affiliations

United States Food and Drug Administration(Current)

Bristol-Myers Squibb (United States)

Pfizer (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Sam Haidar is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and bioanalysis.

Top concepts

MedicinePharmacologyBioanalysisDrug DiscoveryClinical ChemistryChromatographyBiomedical AnalysisBiochemistryAnalytical ChemistryEngineering

Publications per year

1995–2022

31

Publications

31

Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications

Barbara M. Davit, Dale P. Conner, Beth Fabian-Fritsch et al. · The AAPS Journal · 2008 · 127 citations · Full text

Bioequivalence, Pharmacology, Bioequivalence Data Submitted +6

Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance

Brian Booth, Mark E. Arnold, Binodh DeSilva et al. · The AAPS Journal · 2014 · 114 citations · Full text

Fda Guidance, Preclinical Drug Evaluation, Medicine +8

2012 White Paper on Recent Issues in Bioanalysis And Alignment of Multiple Guidelines

Binodh DeSilva, Fabio Garofolo, Mario L. Rocci et al. · Bioanalysis · 2012 · 101 citations

Engineering, White Paper, Multiple Regulatory Agencies +26

Evaluation of a Scaling Approach for the Bioequivalence of Highly Variable Drugs

Sam Haidar, Fairouz Makhlouf, Donald J. Schuirmann et al. · The AAPS Journal · 2008 · 101 citations · Full text

Pharmacokinetic Modeling, Bioequivalence, Medicine +9

Pharmacokinetics, Absolute Bioavailability, and Absorption Characteristics of Lamivudine

Geoffrey J. Yuen, David M. Morris, Patricia K. Mydlow et al. · The Journal of Clinical Pharmacology · 1995 · 86 citations

Rows per page

1–5 of 31